Informazioni
Non ci sono recensioni
Punto di Riferimento
per Medici e Operatori Sanitari
per Medici e Operatori Sanitari
LIBRERIA STUDIUM
Anticancer Treatments and Cardiotoxicity
Mechanisms, Diagnostic and Therapeutic Interventions
Lancellotti, Zamorano, Galderisi
Editore
Elsevier
Anno
2017
Pagine
470
ISBN
9780128025093
108,00 €
DA SCONTARE
Features:
- Provides algorithms essential for the use of imaging, and biomarkers for the screening and monitoring of patients
- Written by world-leading experts in the field of cardiotoxicity
- Includes high-quality images, case studies, and test questions
- Describes the most effective diagnostic and imaging tools to evaluate and predict the development of cardiac dysfunction for those patients undergoing cancer treatment
- List of Contributors
- Foreword
- Preface
- Preamble
- How Big Is the Problem? The Oncologist’s View
- How Big Is the Problem? The Cardiologists’ View
-
Section I: General Considerations
-
Chapter 1. Epidemiology and Trend of Prognosis in Cancer Patients
- Abstract
- References
-
Chapter 2. Categories of Anticancer Treatments
- Abstract
- Further Reading
-
Chapter 3. Classification by Mechanisms of Cardiotoxicity
- Abstract
- Introduction
- Type I Cardiotoxicity
- Type II Cardiotoxicity
- Cardiotoxicity Induced By TKI, VEGF Inhibitors
- Cardiotoxicity Induced by Other Chemotherapy Drugs
- References
-
Chapter 4. Cardiotoxicity of Oncologic Treatments: Is There a Uniform Definition?
- Abstract
- References
-
Chapter 5. The Impact of Radiotherapy
- Abstract
- Mechanisms of Toxicity
- Factors Modulating Radiosensitivity
- References
-
Chapter 1. Epidemiology and Trend of Prognosis in Cancer Patients
-
Section II: Detrimental Effects of Anticancer Drugs and Radiotherapy on the Heart
-
Chapter 6. Lessons From Preclinical Models
- Abstract
- References
-
Chapter 7. Genetic and Epigenetic Risk Factors
- Abstract
- Anthracyclines
- Trastuzumab
- Radiotherapy
- References
-
Chapter 8. Changes of Myocardial Structure and Function
- Abstract
- Introduction
- Anthracyclines
- Clinical Aspects
- Target Therapy
- ErbB2 Inhibitors
- Monoclonal Antibodies
- Proteasome Inhibitors
- Angiogenesis Inhibitors
- Clinical Aspects
- Other Tyrosine Kinase Inhibitors
- Radiation-Induced Cardiomyopathy
- Conclusions
- References
-
Chapter 9. Alteration of Heart Valves
- Abstract
- Introduction
- Pathology of Radiation-Induced Valvular Disease
- Risk Factors and Clinical Manifestations
- Monitoring, Diagnosis, and Management of RIVD
- Conclusions
- References
-
Chapter 10. Pericardial Damage
- Abstract
- References
-
Chapter 11. Effects of Radiotherapy on Vessels and Coronary Arteries
- Abstract
- Pathophysiology and Histopathology
- Coronary Artery Disease
- References
-
Chapter 12. Cardiac Conduction Disturbances
- Abstract
- Physiopathologic Mechanisms
- Clinical Manifestations
- References
-
Chapter 6. Lessons From Preclinical Models
-
Section III: Cardiovascular Complications of Cancer Treatments
-
Chapter 13. Cardiac Rhythm Disturbances
- Abstract
- Introduction
- Rhythm Disturbances Associated With Neoplasms
- Rhythm Disturbances Secondary to Cancer Therapeutics
- Rhythm Disturbances Secondary to Radiotherapy
- QT Prolongation in the Cancer Patient
- Interaction Between Supportive Therapy and Antiarrhythmic Medication
- Conclusion
- References
-
Chapter 14. Acute and Chronic Heart Failure
- Abstract
- Introduction
- Etiology, Demographics, and Prognosis
- Importance of Early Detection and Treatment
- Advanced HF Therapy
- Conclusion
- References
-
Chapter 15. Coronary Artery Disease
- Abstract
- Cancer Therapeutics
- Radiation-Induced Accelerated CAD
- References
-
Chapter 16. Pericardial Effusion and Pericarditis
- Abstract
- Radiotherapy
- Chemotherapy
- References
-
Chapter 17. Radiation-Induced Carotid Atherosclerosis
- Abstract
- References
-
Chapter 18. Valvular Heart Disease
- Abstract
- Preexisting Lesions
- Valve Disease as a Result of the Malignancy
- Valve Disease due to Radiation Therapy
- Valve Disease Related to Infectious Complications of Chemotherapy
- Valve Disease Related to Cardiotoxic Effects of Chemotherapy
- Evaluation of Valvular Disease in Patients With Potential Cardiotoxicity From Cancer Chemotherapeutic Agents
- References
-
Chapter 19. Atrial Fibrillation and Stroke in Cancer Patients
- Abstract
- Introduction
- Cancer and Atrial Fibrillation
- AF Secondary to Cancer Treatment
- Management and Stroke Prevention
- Conclusions
- References
-
Chapter 13. Cardiac Rhythm Disturbances
-
Section IV: Imaging Evaluation of Cardiac Structure and Function in Cancer Patients
-
Chapter 20. The Role of Echocardiography
- Abstract
-
Chapter 20.1. Standard Echo-Doppler Evaluation: LV Systolic and Diastolic Function, Right Ventricular Function, Valvular Heart Disease
- LV Systolic Function
- LV Diastolic Function
- RV Function
- Heart Valve Disease
-
Chapter 20.2. Pericardial Disease in Oncologic Patients
- Etiology
- Diagnosis of Pericardial Disease in Oncologic Patients
- Chapter 20.3. The Role of Contrast Echocardiography
- Chapter 20.4. Stress Echocardiography
-
Chapter 20.5. Advanced Echocardiography: Speckle Tracking Echocardiography and 3D Echocardiography
- Three-Dimensional (3D) Echocardiography
- Speckle Tracking Echocardiography
-
Chapter 21. The Role of Cardiovascular Magnetic Resonance (CMR)
- Abstract
- Introduction
- Standard Analysis of Cardiac Structure and Function
- Tissue Characterization by LGE CMR and T1 Mapping
- References
-
Chapter 22. Nuclear Medicine Imaging and Cardiotoxicity
- Abstract
- Introduction
- References
-
Chapter 20. The Role of Echocardiography
-
Section V: Detection of Cardiac Dysfunction and Predictors of Cardiotoxicity
-
Chapter 23. Detection by Cardiac Imaging: LV Ejection Fraction, Diastolic Dysfunction, Tissue Doppler, and Speckle Tracking Echocardiography
- Abstract
- LV Ejection Fraction
- Diastolic Dysfunction
- Strain Imaging
- Conclusions
- References
-
Chapter 24. The Role of Biomarkers: Troponins, BNP, MPO, and Other Biomarkers
- Abstract
- Troponins
- High-Sensitivity Troponins
- Other Biomarkers
- References
-
Chapter 25. Screening and Comprehensive Follow-Up Evaluation
- Abstract
- An Integrated Approach of Markers and Cardiac Imaging
- Implications of Early Detection on Therapeutic Approach
- Practical Use of Imaging for Follow-Up Evaluation
- Focus on the Patient With Known Cardiac Disease
- References
-
Chapter 26. Preoperative Assessment for Noncardiac Surgery
- Abstract
- Risk Calculation of Perioperative Cardiac Morbidity
- Asymptomatic Patients With Normal LV Function
- Heart Failure
- Symptomatic LV Dysfunction
- Asymptomatic Patients With LV Dysfunction
- Natriuretic Peptides in Perioperative Risk of HF
- References
-
Chapter 23. Detection by Cardiac Imaging: LV Ejection Fraction, Diastolic Dysfunction, Tissue Doppler, and Speckle Tracking Echocardiography
-
Section VI: Cardiotoxicity in Childhood
-
Chapter 27. Cardiotoxicity of Childhood Cancer Treatments
- Abstract
- Childhood Cancer Survival: Preamble
- Chronic Cardiotoxicity and Long-Term Effect of Radiotherapy in Childhood
- Cardiotoxicity Risk Factors in the Pediatric Age
- Detection and Monitoring of Cardiotoxicity in Children
- Prevention of Cardiotoxicity in Children
- References
-
Chapter 27. Cardiotoxicity of Childhood Cancer Treatments
-
Section VII: Management of Anticancer Drugs Related Cardiotoxicity
-
Chapter 28. Nonpharmacologic Therapy
- Abstract
- Risk Factors
- Exercise
- Nutrition and Diet
- Serum Markers
- References
-
Chapter 29. Beta-Blockers
- Abstract
- Physiology of β-Blockers in Cardiotoxicity
- Evidence-Based Data
- Clinical Practice
- References
-
Chapter 30. Angiotensin-Converting Enzyme Inhibition
- Abstract
- Physiology
- Evidence-Based Data
- Clinical Practice
- Angiotensin II Receptor Blockers
- References
-
Chapter 31. Diuretics
- Abstract
- Cardioprotective Treatment
- Symptomatic Treatment
- References
-
Chapter 32. Antiarrhythmic Drugs
- Abstract
- Supraventricular Arrhythmias
- Ventricular Arrhythmias
- Bradycardia, Sinus Node Dysfunction and Conduction Defects
- References
-
Chapter 33. Anticoagulation in Cancer Patients
- Abstract
- Therapeutic Anticoagulation
- Prophylactic Anticoagulation
- References
-
Chapter 34. New Drugs: The Beneficial Effects of Ranolazine
- Abstract
- Ranolazine: Mechanisms of Action
- Rationale for the Use of Ranolazine to Protect From Anticancer Drugs
- Basic and Clinical Researchers on the Use of Ranolazine in the Cancer Setting
- References
-
Chapter 35. Percutaneous Coronary Intervention and Cardiac Surgery in Cancer Patients
- Abstract
- Management of Patients With CAD and Cancer
- Percutaneous Revascularization
- Surgical Revascularization
- Conclusion
- References
-
Chapter 36. Focus on the Patient With Known Cardiac Disease
- Abstract
- Patients with cancer and previous known cardiac disease
- Pre- and Peri-Operative Management of Patients with Cancer and Known Cardiac Disease
- Conclusion
- References
-
Chapter 37. Multidisciplinary Approach to Cardiac Disease in Cancer Patients
- Abstract
- The Concept of Cardio-Oncology
- The Importance of a Preliminary CV Risk Assessment in Cancer Patients
- The Role of a Baseline CV Examination
- The Role of a Cardiologic Follow-Up During Cancer Therapy
- Cardiologic Follow-Up of Cancer Survivors After Therapy Completion
- References
-
Chapter 28. Nonpharmacologic Therapy
-
Section VIII: Future Research Priorities
-
Chapter 38. Pharmacogenomics Screening
- Abstract
- Pharmacogenomics: Background
- Genetic Determinants of Anthracycline-Induced Cardiotoxicity
- Genetic Determinants of Cardiotoxicity of Targeted Therapies
- Conclusions
- References
-
Chapter 39. Cardiac Monitoring During Clinical Trials
- Abstract
- Introduction
- Phased Study Design
- Careful Patient Selection
- Cautious Cardiac Monitoring
- Clear Stopping Rules (Interruption and Discontinuation)
- Sequential Schemes of Anthracycline–Trastuzumab Administration
- Alternative Schemes
- Conclusion and Perspectives for Cardiac Monitoring and Management
- References
-
Chapter 40. Preventive Therapy
- Abstract
- Dexrazoxane
- Statins
- Thalidomide
- Metformin
- References
-
Chapter 41. Cardiotoxicity: Future Research Directions
- Abstract
- How to Predict the Risk of CTRCD
- How to Improve Therapeutic Strategies to Reduce Cardiotoxicity
- References
-
Chapter 38. Pharmacogenomics Screening
- Multiple Choice Questions
- Index
